HUE026644T2 - Mixtúra alacsony és magas molekulatömegû vegyületek transzdermális beadásához - Google Patents
Mixtúra alacsony és magas molekulatömegû vegyületek transzdermális beadásához Download PDFInfo
- Publication number
- HUE026644T2 HUE026644T2 HUE05826138A HUE05826138A HUE026644T2 HU E026644 T2 HUE026644 T2 HU E026644T2 HU E05826138 A HUE05826138 A HU E05826138A HU E05826138 A HUE05826138 A HU E05826138A HU E026644 T2 HUE026644 T2 HU E026644T2
- Authority
- HU
- Hungary
- Prior art keywords
- transdermal delivery
- acid
- composition
- skin
- collagen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M35/00—Devices for applying media, e.g. remedies, on the human body
- A61M35/003—Portable hand-held applicators having means for dispensing or spreading integral media
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00902—Plasters containing means
- A61F2013/00906—Plasters containing means for transcutaneous or transdermal drugs application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Zoology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Inorganic Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (17)
1 > Llpí%őmböt tartalmadé, borön M. mkalmazható készimény, ahol a%îâg0iA SMxitei xsircsoporiol vágy Jipdeseportot. és egy alkalmazott hatóanyagot Äalmaz, ahol a zsiresőport vagy llpídesopert eîoxilezésének tâ&tôké lík 11,; í% 13,: 14, 1¾ 16, 17, IS vagy 19 etmeíezés n»lekeiánkéni, és ahol & zsírcsoport: vagy lípkfcsopmt 19 szén maradékot tartalmaz, Z Μ 1* igénypont szerinti Hin ât alkaimtótato |êsÂÉ8y> amely tartalmaz további vizet.
3. Az 1. igénypont szériát!: i# át alkalmazbatp készítmény amely tartalmaz mváböá alkoholt,
4. Az !... igénypont szerinti: hitön É: alkalmazható készítmény, állöl: a zsiresoport vagy IpiáesopóÉ legalább 1:9 mm maradékok. de légijeié 39 szén matádékrtí tartalmaz,
5. Az 1. igénypont szerinti My& É alkalmazható készítmény, alól az etoxilezés :mennylsege ngyanakkom, rmot a zsitcsoporí: vagy lipide söpört szén mmarlékaipal száma,
6. Az 1, igénypont szerinti horda ai altelmazhato készítmény, alól a zslmsopop vagy iipidesoport MnckosszÉsága 19,12, 14. 16,18,20, 22 vagy 24 szén maradék.
7. Az 1. igénypont szerinti borin át alkalmazható készítmény, ahol a zsírcsoport egy zsírsav. Ü. A 7. igénypont szerinti bitón át alkalmazható készítmény, ahol a zsírsav az alábbiak köréből választott: Cl 6:1, dalla 1; €16:1, delta 2; €16:1, delta 3; €16:1, delta 4; Cl 6:1, delta 3; €19:1, delta 6; C16;l, delta 7; €16:1, delta i:; ClJtl, delta 9 fpalmimlsavy; €16: k delta 10; €16:1, deka 11; €16:1, delta 12; €16:1, delta 13; és €16:1, delta 14. % Az l. Igénypont szérini bőrön át alkalmazható készítmény, ahol á xsíresopert egy zsír-amin, 10; Az igénypont szerinti bőrön át alkalmazható kéSZlhnénl, aboi a lipidesopori szingoltpd, g!lc?llprd vagy glikoszlingolipid.
11. Az: 1. Igénypont szerinti boron al alkalmazható készítmény, ahol a lipldgomb etoxiiezett zsircsoport homogén keverékét, vagy etoxiiezett zsírsavak heterogén keverékét tartalmazza.
12. Az 1. igénypont szerinti bőrön át alkalmazható készítmény, ahol az alkalmazott hatóanyag egy poiipeptid hormon.
13. Az 1. igénypont szerinti bőrön át alMtmtzható készítmény, ahol az alkalmazott hatóanyag kollagén. 14. : Az í. Igénypont smánti bőrön ál alkalmazható készítmény, ahol az alkalmazott hatóanyag: egy érzéstelenítő,
15.. Az X, Igénypont szerinti bőrön át a&almazható készítmény, ahol az alkalmazott Itatóanyag: egy fajdalomcsillapitó,
14. Az 1. Igénypont szerinti bőrön |t alkalmazható készítmény, ahol m alkalntazott hatóanyag egy rmnöszleroid gyulladáscsökkentő hatóanyag (NSA1D) azmláhthak-kötóhől választva: ihnptolen (2~(Ízőhntilfenii)--proplonsav}; ntelotrexat (N-[4~{2:, 4 dlamino 4 * ptóidtói ~ rnetil] metilatnlno] henzoilkL-glhttó«^. aszpirin iaeetlszaleilsav); szalkilsav; dilenkidranún .(2n(Éifenílm«^ sosav):;: naproxén p-nailalén eeetsav, ő-Tnetózi-ü-métE", námnmsó, (*) "$: femlhutazon f4-buti i-1 szoItódak^(2|'5-:nno^2^nmí|l~l-[|;p'«(metiiszultínii}feíiiljníeíilén~|~lll»mdén'3-eéeisav; íiinnizál (2',4\ ^diiuor-d-hídroxírdtóitenilkarboxilsav; piroxkam 2-'heitóotiatón^2rkarbo:xamíd 1, 1-dioxid, oxiesny Indometadn |1-(4-którbenml|}»S” metóxn2ns€til4lrindol'-3'-eeetsavl:; meUofenamál nátrium |Nr(2, Mlklor-mAolE) antmnilsav, náirímnsó, nmnohidraík ketoprotón PA3"benzoílfeml)-pmpÍönsao| lóiméin Bâtions ípátém .1 »moiltó^nÉgílbenzoíl-1 H^Mí>2-acetát dihldrát); diklotérák-nátrium (2~|p,,i-diklórfenil:)amísmltóenzoieemsay mononátrium sók hldroxiklorokin szullát í2iP-|12>>:klőrtó”kinnliI)ahtinolpentiÍ] eíilarninoletano! szollat (1;!); penieíllamm tó-merkapto^P-yálin); ílnrhlprolen {[l.tóhitónij-d-ecetsav, 2-Íoormlfemeil-, (4--); ©lodolak {i4-dtóti!-l3,4,1, íetrahidröplrano'ptó-fölindoktóeeefeax; mvíenamlnsav (hí·· (2J-> dlil)aníraníbav; és ditóntódrarnln sósav ptóiíenl metoxi-N, Ntói-metlletanán sósav).
13, Az 1:, igénypont szeinlt boron $.t alkalmazható Mszíhsény,: ahol az alkalmazott hatóanyag egy gyuHadásosÖkkentó vegyület Ihdrőkortízön, predntzólon, Iriamcínoten, korüzon és piroxikám köréből választva, vagy egy fertőtlenítő vegyük? amoxicillin, klavolinát-kállssp: iírakonazoi;, aeiklovh; hnkonazol, mMmün sósav, entromiéin Piszokéinak aoeiil sxulrizoxazol, penicillin % eetólexm, ©riíromfem, aziîmmioin, Mraslklis, eipMSaxm,: gemamícin, szulfaüazol, m^ofmmî^%: norioxaem, flumekvip. és. Ibaioxacíu, rneíromdazol, nisziarin, kmivudin, indinavir szaliai, és smvodm köréből választva. 14 Az 1 igénypont szerinti hirön át alkalmazható készítmény, ate! m alkalmazott hatóanyag metíormín sósav vagy akarbóz,
19. Az 1. Igénypont szerinti bőrön át alkalmazható készítmény, ahol m. alkalmazott hatóanyag: egy immunogén, példán! egy pokmjkléötidoí tartalmazó immunogen. 24 Az 1, igénypont szerinti bőrén át alkalmazható készítmény, ahol az alkalmazott: hatóanyag égy immunválaszt módosító anyag:. 1L Az 1. igénypont szerinti bőrön It alkalmazható lészítmény, ahol m alkalmazod hatóanyag égy enzim inhibitor zileaton* kaptopril. és fízioopil Imréből válhatva; vagy a hatóanyag otgotamia, melatonin, szumairipián, zohnítripiáo, és rizatriptan köréből választóit' vagy pipidet», zíílpsdem-tartarát, triazolam, & Ihcoszein-bmiítemhl köréből választóit ; vagy jobexol, teehneolnm, Ä9!%£ sestamiki JomeproL gadodiamld, joverzol, és jopromid köréből választóit; vagy aizakttd, amerieiom, betazol, hisztamim mannit, mériPpOP, pétagaszhin, tentóiamin, radioaktív B12, gadodiamah gadopentetmsav, gadoteriiöl, priukron, cihlosporín, szlldenatl! eltiát, pakbtaxel, rttónavig és szakvmavir köréből választott,
22. Az 1-21. igénypontok bármelyike szerinti bőrön át alkalmazható készítmény gyógyszeréit váló alkalmazásra,
23. Az 1 -2 !. igénypontok bármelyike szerinti bőrön át alkalmazható készítmény egy alkalmazott hatóanyag beadására való alkalmazásm,
24. Az 1, igénypont szerinti bőrön át alkalmazható készítmény, ahol a zsircsopori egy ieihetkn zsírsav.
25. Az 1. igénypont szerinti bőrön át alkalmazható készítmény, ahol a zsírcsoport egy többszörösen telítetlen zsírsav, 24 A 12. Igénypont szerinti bőrön át alkalmazható készttmáöy, ahol a polipeptid hormon öxltócln, vazopressxm, nteianoeba-sIlpplÄ hormon, imriiköiröpim lipotropm, pmMmirig^seífentö kormon, növekedési hormon, prolaktm, Inteinizalo hPmoo, huma» chorionic gonadotropin, thszőérést serkentő kormon, korriloixopiP íélpahadíio faktor. gonádotroglm Mtóxkhtd takten ptolaktlnt ösÄtM toktor, polakiät gátló faktor, Âpkedési homroat felszabadító faktor; tirsotmpmt éémMM faktor, kalcitonio., kaidtonfn gén-rokon pepid, atelilkpajzsaürigjf lronaon, glnkagomazerô pepiid I (GOM), glnkozinggö ΙοζοΗηοόόρ :póllpépiM,: gasztrÍB, szókrébn, koleelsztokmin, mötilin, vazoaktfv intósztinábs pepiid, ilmpyag,: lasnyálmitlgy potipepíid, pepid tirozin tirozin, neuropepùd iirozin, amphiregulin (â-EICIk lozolm glokagop, piacontâlts laktogép, relaxia, angioîonztn I), pitvari nätriuretlköS';|i!i^>f|<|) és;molposinfc&fbdî választott.
27. Az L igénypofit nzerinfi bőrön ál alkalmazható készítmény, ahol az alkalmazott hatóanyag égy nem-pèptid: &Öí&ob.
28, Az f... igény pont szerinti bőrön át alkalmazható készítmény, ahol a hormon OfôÂ irijód-titonm, ösztradiol ösztron. progeszteron, íeszíoszteron, koriizol, koríikoszteron, aliosztërOn, opineMópBötépmóífiü, os kálóiról köréből választott. Ä Λ |4 igénypont szerinti borörl át alkalmazható késdtmény, ahol M érzésmienlto artlMn, prokain, íettákátm klOZöpmkain és bohzokalrg BovökÄ, mepívakalm Impívakalm benzokaim és lidokain köréből választolt. 3§. A I S. igénypont szerinti bőrön át alkalmazható készítmény; ahol a Ipdalomcsrllapíié tramadol sósav, föntánl!, motamlzol, morfió-szulíak kétofolao izömetamín, tnfefmdom ppkodott, morfin, lokoptóíen, Capsaiein, és BosweliM köriből választott. 3|, A 20. igénypont szerinti bőrön át alkalmazható készítmény, ahol az. inmnm választ módosító anyag pnrinszármazékok, ademnszármazekok,: ólklosporio és OpGs kömből választott
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2004/017169 WO2005039464A1 (en) | 2003-10-10 | 2004-05-28 | Transdermal high and low molecular weight compounds |
US10/856,567 US7220427B2 (en) | 1998-07-08 | 2004-05-28 | Mixture for transdermal delivery of low and high molecular weight compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE026644T2 true HUE026644T2 (hu) | 2016-07-28 |
Family
ID=37500258
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE05826138A HUE026644T2 (hu) | 2004-05-28 | 2005-05-25 | Mixtúra alacsony és magas molekulatömegû vegyületek transzdermális beadásához |
Country Status (8)
Country | Link |
---|---|
US (2) | US20080154210A1 (hu) |
EP (1) | EP3001990A1 (hu) |
AU (1) | AU2005294805B2 (hu) |
DK (1) | DK1765310T3 (hu) |
ES (1) | ES2560449T3 (hu) |
HK (2) | HK1102290A1 (hu) |
HU (1) | HUE026644T2 (hu) |
PT (1) | PT1765310E (hu) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070248635A1 (en) * | 2006-04-20 | 2007-10-25 | Southerlee Incorporated | Green tea jewelry |
AU2009255619A1 (en) * | 2008-06-04 | 2009-12-10 | Coda Therapeutics, Inc. | Treatment of pain with gap junction modulation compounds |
WO2010039949A1 (en) | 2008-10-02 | 2010-04-08 | Mylan Inc. | Method of making a multilayer adhesive laminate |
ES2755718T3 (es) * | 2009-10-16 | 2020-04-23 | Sixtem Life S R L | Dispositivo para dosificar una o más sustancias de tratamiento para la piel |
MX2012011262A (es) | 2010-04-01 | 2013-02-11 | Pharmanest Ab | Composiciones anestesicas termogelificantes. |
DE202010012043U1 (de) * | 2010-08-31 | 2010-11-11 | Sanderstrothmann Gmbh | Vorrichtung zur Dosierung einer säurehaltigen Zusammensetzung |
US11224659B2 (en) | 2010-10-29 | 2022-01-18 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
US9504664B2 (en) | 2010-10-29 | 2016-11-29 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
US9744132B2 (en) | 2010-10-29 | 2017-08-29 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
US11730709B2 (en) | 2010-10-29 | 2023-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
US9308213B2 (en) | 2010-10-29 | 2016-04-12 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
US9737500B2 (en) | 2010-10-29 | 2017-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
US8895536B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating chronic inflammation and inflammatory diseases |
US10695432B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
US9271950B2 (en) | 2010-10-29 | 2016-03-01 | Infirst Healthcare Limited | Compositions for treating chronic inflammation and inflammatory diseases |
US11202831B2 (en) | 2010-10-29 | 2021-12-21 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
US10695431B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
US10647668B2 (en) | 2011-01-03 | 2020-05-12 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactant and associated method of use |
US9962361B2 (en) | 2011-01-03 | 2018-05-08 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use |
US11279674B2 (en) | 2011-01-03 | 2022-03-22 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactant and associated method of use |
US8933119B2 (en) | 2011-01-03 | 2015-01-13 | The William M. Yarbrough Foundation | Method for treating phytophotodermatitis |
US11407713B2 (en) | 2011-01-03 | 2022-08-09 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use |
US10308599B2 (en) | 2011-01-03 | 2019-06-04 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use |
US10640464B2 (en) | 2011-01-03 | 2020-05-05 | The William M. Yarbrough Foundation | Use of isothiocyanate functional surfactants as Nrf2 inducers to treat epidermolysis bullosa simplex and related diseases |
US10273205B2 (en) | 2011-01-03 | 2019-04-30 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactants, formulations incorporating isothiocyanate functional surfactants and associated methods for treating biofilms |
US8865765B2 (en) | 2011-01-12 | 2014-10-21 | The William M. Yarbrough Foundation | Method for treating eczema |
US9532969B2 (en) | 2011-02-08 | 2017-01-03 | The William M. Yarbrough Foundation | Method for treating psoriasis |
EP2753179A4 (en) * | 2011-09-09 | 2015-03-04 | Univ Leland Stanford Junior | TOPICAL FORMULATIONS OF ITRACONAZOLE AND USES THEREOF |
US10335387B2 (en) | 2012-07-26 | 2019-07-02 | The William M. Yarbrough Foundation | Method for treating infectious diseases with isothiocyanate functional compounds |
US10080734B2 (en) | 2012-07-26 | 2018-09-25 | The William M. Yarbrough Foundation | Method for treating autism and other neurodevelopmental disorders |
US10434082B2 (en) | 2012-07-26 | 2019-10-08 | The William M. Yarbrough Foundation | Isothiocyanate functional compounds augmented with secondary antineoplastic medicaments and associated methods for treating neoplasms |
US9949943B2 (en) | 2012-07-26 | 2018-04-24 | The William M. Yarbrough Foundation | Method for treating neurodegenerative diseases |
WO2014018874A1 (en) | 2012-07-26 | 2014-01-30 | The William M. Yarbrough Foundation | Method for treating skin cancer |
US9839621B2 (en) | 2012-07-26 | 2017-12-12 | The William M. Yarbrough Foundation | Method for treating bladder cancer |
US10434081B2 (en) | 2012-07-26 | 2019-10-08 | The William M. Yarbrough Foundation | Inhibitors of macrophage migration inhibitory factor |
US10441561B2 (en) | 2012-07-26 | 2019-10-15 | The William M. Yanbrough Foundation | Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer |
CA2893768C (en) | 2012-12-07 | 2021-08-24 | Sambria Pharmaceuticals, Llc | Topical preparation for pain relief |
US10265283B2 (en) | 2012-12-07 | 2019-04-23 | Sambria Pharmaceuticals, Llc | Topical composition and delivery system and its use |
WO2014106048A2 (en) * | 2012-12-31 | 2014-07-03 | Jrx Biotechnology, Inc. | Liquid topical pharmaceutical nano-emulsion formulations |
KR101622382B1 (ko) | 2013-02-27 | 2016-05-19 | (주)내츄럴엔도텍 | 경피 흡수 촉진제 및 그의 용도 |
WO2014133344A1 (ko) * | 2013-02-27 | 2014-09-04 | 주식회사 내츄럴엔도텍 | 경피 흡수 촉진제 및 그의 용도 |
US9125892B2 (en) * | 2014-02-03 | 2015-09-08 | George D. Petito | Composition for reduced scar formation of wounds |
US20200375849A1 (en) * | 2019-05-28 | 2020-12-03 | Cmpd Licensing, Llc | Devices and methods for providing medication |
CN108024914A (zh) | 2015-09-17 | 2018-05-11 | Jrx生物技术有限公司 | 改善皮肤的水合作用或润湿作用的方法 |
GB2564026B (en) * | 2016-02-03 | 2022-07-13 | Sbg Medical Tech Inc | Topical composition and delivery system and its use |
EP3518672A4 (en) * | 2016-09-29 | 2020-05-06 | JRX Biotechnology, Inc. | METHOD AND COMPOSITIONS FOR MODIFYING PLANT GROWTH AND REDUCING THE WATER CONSUMPTION OF PLANTS |
US10576256B2 (en) * | 2016-12-13 | 2020-03-03 | Becton, Dickinson And Company | Antiseptic applicator |
RU2694501C1 (ru) * | 2018-01-16 | 2019-07-15 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Кубанский государственный аграрный университет имени И.Т. Трубилина" | Тест-система для обнаружения генома возбудителя ротовируса типа А у сельскохозяйственных животных с помощью мультиплексной полимеразной цепной реакции с флуоресцентной детекцией в режиме реального времени |
US11634368B2 (en) | 2018-03-28 | 2023-04-25 | Jrx Biotechnology, Inc. | Agricultural compositions |
US10285998B1 (en) | 2018-04-04 | 2019-05-14 | The Menopause Method, Inc. | Composition and method to aid in hormone replacement therapy |
WO2020205848A1 (en) * | 2019-04-01 | 2020-10-08 | Geltor, Inc. | Topical formulations of recombinant collagens |
US11793981B2 (en) | 2020-05-21 | 2023-10-24 | Equilibrate Therapeutics, LLC | Microneedle device for control of thyroid hormone levels |
CN111529460B (zh) * | 2020-06-27 | 2023-03-28 | 同芙集团(中国)股份有限公司 | 一种面膜组合物、面膜及其制备方法 |
CN113117359B (zh) * | 2021-03-05 | 2022-08-26 | 湘雅生物医药(湖州)有限公司 | 一种用于胶原蛋白提取用的无菌式蒸馏瓶 |
CN113336842A (zh) * | 2021-04-14 | 2021-09-03 | 海南三元星生物科技股份有限公司 | 一种胶原蛋白肽的制备方法 |
WO2024064264A2 (en) * | 2022-09-21 | 2024-03-28 | Lile Method Research, Llc | Compositions and methods for increasing glutathione levels |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3829641A1 (de) * | 1988-09-01 | 1990-03-15 | Roecar Holdings Nv | Transdermal anwendbare pharmazeutische zubereitungen mit sterolinen und/oder spiroketalinen |
US5297562A (en) | 1991-04-01 | 1994-03-29 | President And Fellows Of Harvard College | Method for detecting and treating Alzheimer's disease |
US5614212A (en) | 1992-04-08 | 1997-03-25 | International Medical Associates, Inc. | Method of transdermally administering high molecular weight drugs with a polymer skin enhancer |
US5318960A (en) | 1992-06-03 | 1994-06-07 | Frank Toppo | System for transdermal delivery of pain relieving substances |
KR940021073A (ko) | 1993-03-02 | 1994-10-17 | 미야베 요시가즈 | 알쯔하이머병의 예방 또는 치료제, 그 스크리닝 방법 및 인간 유래의 타우 단백질 키나아제 i |
US5840746A (en) | 1993-06-24 | 1998-11-24 | Merck Frosst Canada, Inc. | Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases |
US5744368A (en) | 1993-11-04 | 1998-04-28 | Research Foundation Of State University Of New York | Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR) |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
ATE328890T1 (de) | 1994-07-15 | 2006-06-15 | Univ Iowa Res Found | Immunomodulatorische oligonukleotide |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US5665378A (en) | 1994-09-30 | 1997-09-09 | Davis; Roosevelt | Transdermal therapeutic formulation |
DE19509079A1 (de) * | 1995-03-15 | 1996-09-19 | Beiersdorf Ag | Kosmetische oder dermatologische Mikroemulsionen |
JP3380368B2 (ja) | 1995-06-05 | 2003-02-24 | 三菱電機株式会社 | 車両用盗難防止装置 |
US5891857A (en) | 1996-02-20 | 1999-04-06 | Vanderbilt University | Characterized BRCA1 and BRCA2 proteins and screening and therapeutic methods based on characterized BRCA1 and BRCA2 proteins |
JPH09255926A (ja) | 1996-03-26 | 1997-09-30 | Diatex Co Ltd | 粘着テープ |
US5891651A (en) | 1996-03-29 | 1999-04-06 | Mayo Foundation For Medical Education And Research | Methods of recovering colorectal epithelial cells or fragments thereof from stool |
US5861268A (en) | 1996-05-23 | 1999-01-19 | Biomide Investment Limited Partnership | Method for induction of tumor cell apoptosis with chemical inhibitors targeted to 12-lipoxygenase |
US5708038A (en) | 1996-06-13 | 1998-01-13 | Univera Pharmaceuticals, Inc. | Method of using aloe vera as a biological vehicle |
NZ329798A (en) | 1996-07-03 | 1999-04-29 | Japan Energy Corp | Purine derivatives their tautomers and salts thereof and interferon secretion inducers, antiviral agents and anticancer drugs containing the same |
US6387938B1 (en) | 1996-07-05 | 2002-05-14 | Mochida Pharmaceutical Co., Ltd. | Benzimidazole derivatives |
US5936107A (en) | 1996-12-09 | 1999-08-10 | Henkel Kommanditgesellschaft Auf Aktien | Process for the production of fatty acid polyethylene glycol esters |
EP0894797A4 (en) | 1997-01-09 | 2001-08-16 | Terumo Corp | NEW AMID DERIVATIVES AND INTERMEDIATES ON YOUR SYNTHESIS |
US5945446A (en) | 1997-02-10 | 1999-08-31 | Laubc Biochemicals, Corporation | Process for preparing synthetic soil-extract materials and medicaments based thereon |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
US6426334B1 (en) | 1997-04-30 | 2002-07-30 | Hybridon, Inc. | Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal |
US6339068B1 (en) | 1997-05-20 | 2002-01-15 | University Of Iowa Research Foundation | Vectors and methods for immunization or therapeutic protocols |
US6300508B1 (en) | 1997-07-30 | 2001-10-09 | Henkel Kommanditgesellschaft Auf Aktien | Thickened aqueous surfactant solutions |
US5885597A (en) | 1997-10-01 | 1999-03-23 | Medical Research Industries,Inc. | Topical composition for the relief of pain |
EP1035123B1 (en) | 1997-11-28 | 2003-08-20 | Sumitomo Pharmaceuticals Company, Limited | Novel heterocyclic compounds |
TW572758B (en) | 1997-12-22 | 2004-01-21 | Sumitomo Pharma | Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives |
US6946144B1 (en) * | 1998-07-08 | 2005-09-20 | Oryxe | Transdermal delivery system |
JP2000119271A (ja) | 1998-08-12 | 2000-04-25 | Hokuriku Seiyaku Co Ltd | 1h―イミダゾピリジン誘導体 |
WO2000075304A1 (fr) | 1999-06-08 | 2000-12-14 | Aventis Pasteur | Oligonucleotide immunostimulant |
DK1200580T3 (da) | 1999-08-13 | 2005-04-11 | Hybridon Inc | Modulering af oligonukleotid-CpG-medieret immunstimulering ved positionel modifikation |
PT1233782E (pt) | 1999-12-01 | 2009-02-13 | Novartis Vaccines & Diagnostic | Estimulação da produção de anticorpos específicos para o hcv |
US6582724B2 (en) * | 1999-12-16 | 2003-06-24 | Dermatrends, Inc. | Dual enhancer composition for topical and transdermal drug delivery |
EP1242441A4 (en) | 1999-12-17 | 2004-04-14 | Merck & Co Inc | POLYNUCLEOTIDE VACCINES EXPRESSING CODON-OPTIMIZED NEF HIV-1 PROTEIN AND MODIFIED HIV-1 NEF PROTEIN |
WO2001046393A2 (en) | 1999-12-21 | 2001-06-28 | E.I. Du Pont De Nemours And Company | Aspartate kinase |
SK11202002A3 (sk) | 2000-02-09 | 2003-03-04 | Hokuriku Seiyaku Co., Ltd. | Deriváty 1H-imidazopyridínu |
DE10036282A1 (de) | 2000-07-26 | 2002-02-07 | Bosch Gmbh Robert | Verfahren und Vorrichtung zur Steuerung einer Antriebseinheit |
UA79764C2 (en) | 2001-11-27 | 2007-07-25 | Anadys Pharmaceuticals Inc | 3-?-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF |
WO2004058808A2 (en) | 2002-03-22 | 2004-07-15 | U.S. Army Medical Research Institute Of Infectious Diseases | Dna vaccines against hantavirus infections |
US20030235610A1 (en) * | 2002-06-21 | 2003-12-25 | Piedmont Pharmaceuticals, Llc | Liposomes containing biologically active compounds |
EP1578766B1 (en) | 2002-12-03 | 2013-02-13 | University of Massachusetts | Polyvalent, primary hiv-1 glycoprotein dna vaccines and vaccination methods |
AU2003303561A1 (en) | 2002-12-27 | 2004-07-29 | Collins And Aikman Products Co. | Trunk compartment latch cover |
MXPA05010255A (es) | 2003-03-24 | 2005-12-14 | Scripps Research Inst | Vacunas de adn contra crecimiento tumoral y metodos de uso de las mismas. |
WO2004110483A1 (en) | 2003-05-31 | 2004-12-23 | Yiyou Chen | Method and composition of a novel vaccine design for the prevention and treatment of sars |
US9507404B2 (en) | 2013-08-28 | 2016-11-29 | Via Technologies, Inc. | Single core wakeup multi-core synchronization mechanism |
-
2005
- 2005-05-25 AU AU2005294805A patent/AU2005294805B2/en active Active
- 2005-05-25 ES ES05826138.9T patent/ES2560449T3/es active Active
- 2005-05-25 US US11/597,700 patent/US20080154210A1/en not_active Abandoned
- 2005-05-25 HU HUE05826138A patent/HUE026644T2/hu unknown
- 2005-05-25 DK DK05826138.9T patent/DK1765310T3/en active
- 2005-05-25 PT PT58261389T patent/PT1765310E/pt unknown
- 2005-05-25 EP EP15169877.6A patent/EP3001990A1/en not_active Withdrawn
-
2007
- 2007-09-24 HK HK07110356.0A patent/HK1102290A1/zh unknown
-
2013
- 2013-12-19 US US14/135,439 patent/US20140200531A1/en not_active Abandoned
-
2016
- 2016-09-20 HK HK16111013.2A patent/HK1222789A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
PT1765310E (pt) | 2016-03-01 |
AU2005294805B2 (en) | 2012-02-16 |
EP3001990A1 (en) | 2016-04-06 |
HK1222789A1 (zh) | 2017-07-14 |
DK1765310T3 (en) | 2016-01-11 |
HK1102290A1 (zh) | 2007-11-16 |
US20140200531A1 (en) | 2014-07-17 |
ES2560449T3 (es) | 2016-02-19 |
AU2005294805A1 (en) | 2006-04-20 |
US20080154210A1 (en) | 2008-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1765310T3 (en) | MIXING for transdermal delivery of LAV AND HØJMOLEKYLVÆGTFORBINDELSER | |
US7300666B2 (en) | Mixture for transdermal delivery of low and high molecular weight compounds | |
US6946144B1 (en) | Transdermal delivery system | |
KR100648536B1 (ko) | 침투 보강 및 자극 감소를 위한 계 | |
JP5144277B2 (ja) | 局所用生体付着性製剤 | |
JP5731446B2 (ja) | 局所用生体付着性製剤 | |
TW201521758A (zh) | 用於使皮膚回春之胜肽及其使用方法 | |
EP1765310B1 (en) | A mixture for transdermal delivery of low and high molecular weight compounds | |
TR201808178T4 (tr) | Aktif ajanların transdermal dağıtımı için bileşimler. | |
JP2009184951A (ja) | 皮膚外用剤組成物 | |
PT1853303E (pt) | Composições estabilizadas para administração tópica, e métodos para a sua preparação | |
JP5732471B2 (ja) | 溶媒混合物およびビタミンd誘導体から成る医薬品組成物または類似体 | |
EP1684681B1 (en) | A mixture for transdermal delivery of low and high molecular weight compounds | |
WO2000002601A2 (en) | Transdermal delivery system | |
AU2012200101A1 (en) | A mixture for transdermal delivery of low and high molecular weight compounds | |
JP2016530287A (ja) | 過角化性の皮膚病変の治療を目的とする、角質溶解薬としてのトルフルオロ酢酸またはその生理学的に許容される塩の使用 |